Rather than alleviating NASH by specifically reducing the expression of a particular gene, SG seems to restore insulin sensitivity (Figure 9G), inhibit fatty acid synthesis (Figure 9E), and reduce lipid deposition in the liver by attenuating the expression of FASN, SCD1, and HMGCS1 (Figure 9H). The gene discussed is FASN; the disease is metabolic dysfunction-associated steatohepatitis.